June Almenoff

Dr. June Almenoff is the current Chief Scientific Officer at RedHill Biopharma. June has held numerous positions at biopharma companies and clients, including Furiex Pharmaceuticals, GlaxoSmithKline, and Duke University Medical Center. Dr. Almenoff has been instrumental in the development and approval of several novel drugs, including Viberzi for diarrhea-predominant irritable bowel syndrome. June is a respected authority in the field of clinical safety and pharmacovigilance, and their work has helped to improve the lives of countless patients.

June Almenoff's educational career includes a BA in biochemistry from Smith College, an MD and PhD from Mt. Sinai School of Medicine (now Icahn School of Medicine) through a dual degree program in medicine and pharmacology, and a residency in internal medicine and infectious diseases at Stanford University School of Medicine.

They are on a team with Valerie Graceffa - VP, US Sales, Gilead Raday - Chief Operating Officer, and Clara Fehrmann - Director of Clinical Operations. Their manager is Dror Ben-Asher, CEO.